Innoviva, Inc. (HVE.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 09:16AM CEST
| Previous close | 14.70 |
| Open | 14.60 |
| Bid | 14.70 x 33200 |
| Ask | 14.80 x 32300 |
| Day's range | 14.60 - 14.60 |
| 52-week range | 11.00 - 15.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 911.694M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 7.09 |
| EPS (TTM) | 2.06 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 08 Sept 2015 |
| 1y target est | N/A |
- GuruFocus.com
Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
Strong Performance with Significant Growth in Net Product Revenue
Simply Wall St.Innoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)
Innoviva ( NASDAQ:INVA ) First Quarter 2024 Results Key Financial Results Revenue: US$77.5m (up 1.5% from 1Q 2023). Net...
Business WireInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.
© 2024 Yahoo. All rights reserved.